Objective-Vitamin K-dependent proteins (VKDPs), which require post-translational modification to achieve biological activity, seem to contribute to thrombus formation, vascular calcification, and vessel stiffness. Whether VKDP activity is prospectively associated with incident cardiovascular disease has not been studied. Approach and Results-VKDP activity was determined by measuring circulating des-γ-carboxy prothrombin concentrations in a random sample of 709 multiethnic adults free of cardiovascular disease drawn from the Multi-Ethnic Study of Atherosclerosis (MESA). Lower des-γ-carboxy prothrombin concentrations reflect greater VKDP activity. Subjects were followed up for the risk of ischemic cardiovascular disease (coronary heart disease, stroke, and fatal cardiovascular disease) for 11.0 years of follow-up. A total of 75 first ischemic CVD events occurred during follow-up. The incidence of ischemic cardiovascular disease increased progressively across des-γ-carboxy prothrombin quartiles, with event rates of 5.9 and 11.7 per 1000 person-years in the lowest and highest quartiles. In analyses adjusted for traditional cardiovascular risk factors and measures of vitamin K intake, a doubling of des-γ-carboxy prothrombin concentration was associated with a 1.53 (95% confidence interval, 1.09-2.13; P=0.008) higher risk of incident ischemic cardiovascular disease. The association was consistent across strata of participants with diabetes mellitus, hypertension, renal impairment, and low vitamin K nutritional intake. Conclusions-In this sample of middle-aged and older adults, VKDP activity was associated with incident ischemic cardiovascular events. Further studies to understand the role of this large class of proteins in cardiovascular disease are warranted.
V itamin K-dependent proteins (VKDPs) are a large class of proteins unified by their reliance on post-translational modification to achieve biological activity. To date, 19 VKDPs have been described, with important roles in coagulation, platelet function, and vascular biology. Prothrombin, the most welldescribed VKDP, is produced within the liver and circulates systemically until stimulation by a platelet plug, facilitating thrombus formation. Matrix Gla protein (MGP) 1 is produced within vascular smooth muscle cells and inhibits vascular calcification by binding extracellular calcium. 2 Growth arrestspecific factor 6 (Gas6) is produced within platelets and the vascular wall and affects thrombus formation and cell survival. 3 Periostin, 4 expressed in the cardiac ventricle, has a role in ventricular hypertrophy, 5 valvular function, and atherosclerosis. 6 Produced in an inactive form, all VKDPs obtain biological activity through the conversion of a glutamic acid residue into glutamate, a complex process requiring vitamin K hydroquinone as a cofactor and regulated by γ-carboxylase enzyme within the endoplasmic reticulum. In this process, vitamin K hydroquinone is converted to vitamin K epoxide, which in turn is recycled back to vitamin K hydroquinone by vitamin K epoxide reductase. In addition to adequate vitamin K, enzyme activity and polymorphisms affect the carboxylation process, suggesting that the post-translational modification of such proteins have multiple levels of control.
Given the pleiotropic biological effects of this large class of proteins and emerging evidence for their role in cardiovascular physiology, we investigated whether VKDP activity was associated with cardiovascular disease in a well-characterized sample of adults drawn from across the United States. Because prothrombin rapidly undergoes carboxylation before being secreted from the liver, we measured circulating des-γcarboxy prothrombin (DCP) concentrations to indicate lower VKDP activity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Baseline characteristics stratified by DCP quartiles are presented in Table 1 . Participants with higher DCP concentrations (ie, lower VKDP activity) tended to be older, with higher body mass index and cholesterol medication usage, with lower renal function, and with less overall physical activity. The rates of diabetes mellitus and hypertension were similar, but high-sensitivity C-reactive protein (hs-CRP) concentrations increased across the DCP quartiles. As expected, increased phylloquinone concentrations, reflecting greater dietary vitamin K intake, were associated with lower DCP concentrations, reflecting greater VKDP activity. The weighted correlation 
Mean (SDs) are provided. Sample n=709, except cigarette smoking, n=706; pack-years of smoking, n=701; intentional physical activity, n=706; highschool graduate, n=706; diabetes mellitus, n=708; LDL-C, n=701; HDL-C, n=708; triglycerides, n=708; estimated GFR, n=708; urinary albumin/creatinine, n=706; phylloquinone, n=630; dihydrophylloquinone, n=630. Descriptive statistics are not weighted for case-cohort design. BP indicates blood pressure; DCP, des-γ carboxy prothrombin; eGFR, estimated glomerular filtration rate based on creatinine measurement; HDL, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent; and Q, quartile.
between DCP and phylloquinone concentrations was inverse, as expected, but modest (r=−0.11; P=0.006). A total of 84% of the cohort participants had a DCP >2 ng/mL (considered the threshold for VKDP inactivity), whereas 52% had a phylloquinone concentration <1 nmol/L (considered the threshold for inadequate vitamin K intake). In keeping with previous reports suggesting higher dietary vitamin K intake in those of Chinese descent, 7 the majority of Chinese participants (55%) were in the lowest DCP quartile compared with only 15% of white participants ( Figure 1 ).
We documented 75 first ischemic CVD events during a median of 11.0 years of follow-up, 16 myocardial infarctions, 29 coronary revascularization procedures, 22 fatal and nonfatal strokes, and 8 other fatal coronary heart disease events. Unadjusted cumulative incidence rates per DCP quartile are presented in Figure 2 . In general, ischemic CVD incidence rates were higher with greater concentration of DCP.
We next assessed the dose-response relationship of DCP with ischemic CVD (Figure 3 ), which suggested a log-linear association of DCP with CVD incidence. We subsequently performed analyses of log-transformed DCP concentrations with risk, adjusting sequentially for demographics, cardiovascular risk factors, and measures of vitamin K intake. In these analyses (Table 2) , a doubling of circulating DCP concentration was associated with ≈50% higher risk of ischemic CVD. The magnitude of this association was little changed with adjustment for traditional risk factors or phylloquinone concentrations. Given the previously recommended threshold of 2 ng/mL in DCP concentrations to indicate VKDP inactivity, we examined this cut point in fully adjusted models, with an adjusted hazard ratio of 3.42 (95% confidence interval, 0.97-12.09; P=0.06).
The association of DCP concentrations and ischemic CVD seemed to be consistent across a broad range of subgroups. We found no significant interaction of DCP with diabetes mellitus, hypertension, vitamin K intake, or hs-CRP (all multiplicative interaction terms, P>0.5).
Finally, redefining ischemic CVD to include only cardiacrelated events, DCP concentrations were associated with 1.46 (95% confidence interval, 1.00-1.06; P=0.047), 1.59 (95% confidence interval, 1.03-2.44; P=0.035), and 1.53 (95% confidence interval, 1.00-2.35; P=0.054) odds of incident disease using models I, II, and III, respectively.
Discussion
In this population of adults followed up for 11 years, baseline measures of VKDP activity were associated with incident ischemic cardiovascular disease. Our findings raise awareness of this important class of proteins as a potential contributor to cardiovascular disease.
A large body of evidence relates VKDPs to cardiovascular disease. Early animal studies suggested that warfarin administration, a potent inhibitor of vitamin K epoxide reductase recycling, induces widespread medial vascular calcification, 8, 9 otherwise known as Monckeberg calcification. Medial calcification has been associated with vascular stiffness 10 and increased mortality 11, 12 and is prevalent among individuals with diabetes mellitus and chronic kidney disease. MGP has received considerable attention as the candidate VKDP protein responsible for the vascular calcification phenotype. 13 MGP null mice have widespread vascular calcification, 1 and the circulating form of uncarboxylated MGP has been associated with vascular calcification in clinical studies. [14] [15] [16] [17] Because dietary vitamin K may reduce the inactive form of MGP, 18 dietary vitamin K intake has been hypothesized as a determinant of vascular calcification. Animal models have shown regression of vascular calcification with high vitamin K diets, 19 but clinical data have not been uniform, with some studies suggesting a potential benefit of dietary vitamin K, 20,21 not supported by others. 22, 23 A randomized trial of vitamin K for this indication is ongoing. 24 Given the pleiotropic biological roles of VKDPs, it is plausible that VKDPs have a role in CVD independent of any potential effect on vascular calcification. Gas6, widely expressed in vascular smooth muscle cells and monocytes, has received increasing attention for its role in platelet aggregation, vascular morphology, and atherosclerosis. Posttranslational change of the N terminus of Gas6 confers the protein the ability to bind to aninonic phospholipids exposed on injured cell surfaces, 25 and through a family of TAM receptors, Gas6 has multiple downstream effects, including promoting cell survival, 26 migration, 27 and remodeling, and potentially reducing atherosclerotic plaque formation. 28, 29 In addition, Gas6 inhibits the adhesion of leukocytes to endothelial cells 30 and reduces plaque inflammation in some, 31 but not all, 32 studies. Gas6-deficient mice have defective platelet signaling but also seem to have a paradoxical protection against thromboembolic disease. 33 Thus, it is plausible that a generalized state of VKDP inactivity, as measured by increasing DCP concentrations, might also reflect a state of Gas6 inactivity 34 and a consequent proatherosclerotic state. Periostin 4 is a newly described VKDP, named because of its localization in cortical bone periosteum and the periodontal ligament, with a role in embryonic cardiac development 35 and cardiac remodeling. 5 Periostin knockout (Pn −/− ) mice have an increased rate of ventricular rupture after myocardial infarction, 36 but increased periostin expression is also seen in ventricular hypertrophy and fibrosis. 37 In addition, prothrombin itself has been linked to CVD, associated with an increased risk of venothrombotic disease 38 but not arterial disease. 39 In addition to the potential role of VKDPs in thrombus formation and vessel morphology, data suggest an association between VKDPs and inflammation. Administration of high-dose dietary vitamin K reduces inflammatory gene expression in animal models. 40, 41 In our cohort, hs-CRP concentrations increased with greater VKDP inactivity. Given data suggesting that prothrombin is an acute phase reactant, whether increasing DCP concentrations reflect prothrombin production or a carboxylation failure is uncertain although the association of DCP with ischemic cardiovascular disease was consistent across strata of hs-CRP. In our cohort, the weighted correlation for hs-CRP and DCP was r=0.10 (P=0.006).
Our findings add to clinical data linking VKDP activity and cardiovascular disease. In a community-based study of >4800 subjects, dietary vitamin K intake was inversely associated with incident cardiovascular disease. 42 Because most American diets meet the recommended daily vitamin K allowances, there are likely dietary independent factors affecting VKDP activity. The function of the γ-carboxylase enzyme, responsible for converting a glutamic acid to glutamate residue, is impaired in kidney disease 43 and diabetes mellitus, 44 perhaps accounting for the unexpectedly high prevalence of VKDP inactivity in chronic kidney disease. 45 In our analysis, the overall correlation between serum phylloquinone and DCP concentrations was low, potentially supporting a role for dietary-independent factors, although phylloquinone concentrations may also be more sensitive to recent vitamin K intake than are DCP levels. Although high doses of dietary vitamin K can improve VKDP activity, whether such treatment will lead to an improvement of outcomes is speculative.
The strengths of our study included a well-characterized multiethnic population with adjudicated, prospectively measured end points and detailed phenotyping of cardiovascular risk factors. In addition, measurement of serum phylloquinone concentrations allowed the effect of VKDP Non-events ICD Events activity on cardiovascular disease to be adjusted for nutritional vitamin K. Our study also has important limitations. The correlation between the activity of circulating VKDPs, such as prothrombin, and organ-specific VKDPs, such as periostin or MGP, is not known, and the assumption that DCP concentrations reflect overall VKDP activity cannot be validated without further study. Although this is the largest prospective study of DCP and cardiovascular disease to be performed to our knowledge, we only measured DCP in a subcohort of Multi-Ethnic Study of Atherosclerosis (MESA) participants and had limited power to examine associations within subgroups or across components of our composite end point. Nevertheless, increasing DCP quartiles had incrementally higher risks of incident CVD that when examined continuously had sufficient power to detect a significant overall association between DCP and incident CVD. Further research to understand the role of VKDPs in cardiovascular disease is warranted, including a better understanding of the factors that affect post-translational carboxylation of VKDPs, the association between hepatic, platelet, and vascular smooth muscle cell VKDPs, and potential mechanisms of ischemia. In summary, our analysis suggests that VKDP activity is associated with incident ischemic cardiovascular disease. Our results raise the possibility that dietary or pharmacological improvement of VKDP activity can reduce the incidence of CVD. The table shows hazard ratio (95% confidence interval). All models are weighted for case-cohort design and use robust SEs. Model 1: adjusted for age, sex, and race/ ethnicity. Model 2: adjusted for model 1+body mass index, cigarette smoking (never, former, and current), education (high-school graduate), diabetes mellitus, systolic blood pressure, antihypertension medication use, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-reactive protein, lipid-lowering medication, estimated glomerular filtration rate, albumin and creatinine ratio, intentional physical activity, and current alcohol use. Model 3: adjusted for model 2+phylloquinone and dihydrophylloquinone. DCP indicates des-γ carboxy prothrombin; and Q, quartile.
